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Long-chain polyunsaturated fatty acids (LCPUFA) are indispensable for 
normal infant growth and development.  Docosahexaenoic acid (DHA, 22:6n-3) and 
arachidonic acid (ARA, 20:4n-6) are LCPUFA that play a critical role in central 
nervous system development.  During the brain growth spurt, rapid accumulation of 
LCPUFA occurs in the brain and retina.  Currently, insufficient evidence exists to 
determine optimal levels of dietary LCPUFA required during the perinatal period.  
 In the context of a safety and efficacy study of dietary LCPUFA in baboon 
neonates, we examined the influence of medium and high levels of formula DHA 
levels on tissue fatty acid composition and hematological and clinical chemistry 
measures.  Infant formulas were fed from birth to 12 weeks of age: Control (C, no 
DHA/ARA); 1× LCPUFA (L, 0.32%DHA/0.64%ARA); 3× LCPUFA (L3, 
0.96%DHA/0.64%ARA).  
  At 12 weeks, tissue DHA levels were more sensitive to dietary manipulations 
than ARA.  While DHA in the cerebral cortex increased with higher concentrations of 
DHA, no differences between L and L3 were detected in the basal ganglia and limbic 
system.  These findings indicate that current levels of LCPUFA in infant formula are 
not sufficient to optimize DHA levels in the developing cortex.   
RBC, hematocrit, hemoglobin, and red blood cell distribution width (RDW) 
were significantly elevated by formula DHA and ARA.  All erythrocyte values were 
 within accepted normal ranges for infant baboons and no differences were detectable 
at 12 weeks.  These data provide the first indication that dietary LCPUFA may 
influence hematopoiesis during the first weeks of life and mitigate the precipitous 
decline in red cell values associated with neonatal anemia.   
 All clinical chemistry parameters were normal up to 12 weeks of age.  Many of 
the trends observed were similar to those documented in human infant development.  
No negative effects on growth measures, hematological or clinical assessments were 
observed between formula groups.  These results suggest that levels of DHA higher 
than presently included in US infant formulas enhance cerebral cortex DHA and may 
provide additional benefits by improving erythropoiesis.  They also provide a basis for 
interpretation of parallel human infant studies currently underway.          
 
 iii 
BIOGRAPHICAL SKETCH 
Andrea T. Hsieh was born on October 21, 1978 in Elmhurst, Illinois.  She was 
the oldest of four children and spent her childhood and adolescent years in the 
sprawling suburbs of Chicago.  She attended the University of Illinois Urbana-
Champaign and received a Bachelors of Science in Biochemistry.  In 2000, she moved 
to Ithaca, NY and joined the Division of Nutritional Sciences at Cornell University. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv 
 
ACKNOWLEDGMENTS 
To my advisor, Dr. J. Thomas Brenna- thank you for your tremendous 
guidance, infinite patience, endless humor and confidence in me.  A special thanks for 
the numerous trips to Rudy’s BBQ during the SFBR experience.   
I would like to express my sincere appreciation to the members of my 
committee, Dr. Steven S. Robertson, Dr. Linda M. Nowak, and Dr. Barbara J. Strupp 
for valuable discussions during initial stages of this work.  
I acknowledge Dr. Peter Nathanielsz and Dr. Natalia Schlabritz-Loutsevitch 
for their continued support and gracious hospitality during my time at the Southwest 
Foundation for Biomedical Research.  A heartfelt thanks goes to Dr. Cun Li and 
Dongbin Xie for their assistance, encouragement and kindness in San Antonio, TX. 
An enormous thank you to members of the Brenna group, especially Pete 
Lawrence, Carolyn Tschanz, Dr. Srisatish Devapatla, Rinat Ran-Ressler, Gavin Sacks, 
Bruce Pan, Kumar Kothapalli, Behzad Varamini and my favorite undergraduates Evan 
Walther and Tara Kelly for all the lovely times in the basement of Savage Hall.  My 
appreciation also goes to Françoise Vermeylen for her statistical knowledge and 
endurance for answering SAS questions.   
 I would like to acknowledge past and present Nutritional Science students, 
especially Anne LeBourg, Nkosi and Mdu Mbuya, Dave Buress, Natalie Nicod, Krista 
Kauppinen, Samantha Morley, Li Ling Lee, Christina Nyhus, Sera Young, Tim Sontag 
and Greg Jackson for your invaluable friendships and gorges Ithaca memories.  
Thanks to Sara Gulbrandsen, Ivana Lukaska, Jennie Jiang, Peg Smith and Sara 
Wettling for the wonderful Ithaca visits and adventures deep in the heart of Texas.  A 
very special thank you goes to my favorite Romanian mathematician, Radu Murgescu 
for a fabulous final year at Cornell. 
 v 
 Last but not least, I would like to thank my parents, Joyce and Victor for their 
unconditional support and everlasting love.  Thanks to my siblings Philip, Roger and 
Emilie for all the trips to Ithaca, the Underground Railroad escapade and the 12+ hour 
car ride with the mischievous Babycat. 
 
 vi 
TABLE OF CONTENTS 
CHAPTER 1. INTRODUCTION        
1.1 BACKGROUND           1 
1.2 METABOLISM OF n-3 AND n-6 FATTY ACIDS      1 
1.3 ESSENTIAL FATTY ACID DEFICIENCY       6 
1.4 ESSENTIAL FATTY ACID CONVERSION TO LCPUFA     8 
1.5 LCPUFA SYNTHESIS IN NEONATES        8 
1.6 LCPUFA DURING THE PERINATAL PERIOD      9 
1.7 NHP MODELS FOR HUMAN INFANT DEVELOPMENT AND FA  
      METABOLISM          12          
1.8 INFLUENCE OF LCPUFA ON INFANT NEURODEVELOPMENT AND  
      GROWTH            13 
1.9 LCPUFA IN HUMAN MILK AND INFANT FORMULA    18 
1.10 SUMMARY          22 
1.11 REFERENCES          23 
CHAPTER 2. THE INFLUENCE OF MODERATE AND HIGH LEVELS OF  
LONG CHAIN POLYUNSATURATED FATTY ACID (LCPUFA)  
SUPPLEMENTATION ON BABOON NEONATE TISSUE FATTY  
ACIDS          
2.1 ABSTRACT          30 
2.2 INTRODUCTION         31 
2.3 MATERIALS AND METHODS        33 
 2.3.1 Animals          33 
 2.3.2 Diets          33 
 2.3.3 Growth          34 
 2.3.4. Sampling         34 
 vii 
2.3.5 Fatty Acid Analyses         36 
 2.3.6 Statistics           36 
2.4 RESULTS 
 2.4.1 Formula Consumption and Growth       37 
 2.4.2 RBC and Plasma Fatty Acids        37 
2.4.3 Liver and Heart Fatty Acids        38 
2.4.4 Retina Fatty Acids           38 
2.4.5 Central Nervous System Fatty Acids       39 
2.5 DISCUSSION           51 
2.6 CONCLUSION           54 
2.7 ACKNOWLEDGEMENTS         55 
2.8 REFERENCES                      56 
CHAPTER 3. FORMULA DOCOSAHEXAENOIC ACID AND  
ARACHIDONIC ACID IMPROVES POSTNATAL HEMOGLOBIN  
AND RELATED INDICES IN TERM BABOON NEONATES 
3.1 ABSTRACT           59 
3.2 INTRODUCTION          60 
3.3 MATERIALS AND METHODS    
3.3.1 Animals and Diets         62 
 3.3.2 Blood Sampling          63 
 3.3.3 Hematology          63 
 3.3.4 Statistics           64 
3.4 RESULTS AND DISCUSSION         64 
3.5 CONCLUSION           74 
3.6 ACKNOWLEDGEMENTS         75 
3.7 REFERENCES           76 
 viii 
CHAPTER 4. BIOCHEMICAL AND HEMATOLOGICAL PROFILES OF 
BABOON NEONATES CONSUMING FORMULAS WITH 
MODERATE AND HIGH DIETARY LONG-CHAIN  
POLYUNSATURATED FATTY ACIDS  
4.1 ABSTRACT           80 
4.2 INTRODUCTION                     81 
4.3 MATERIALS AND METHODS 
4.3.1 Animals and Diets            82 
 4.3.2 Blood Sampling          83 
 4.3.3 Clinical Chemistry and Hematology                                                       83 
 4.3.4 Statistics           84 
4.4 RESULTS AND DISCUSSION 
4.4.1 Clinical Chemistry         85
 4.4.2 White Cell Measurements        89  
4.5 CONCLUSION           92 
4.6 ACKNOWLEDGEMENTS         92 
4.7 REFERENCES           93 
 
CHAPTER 5. CONCLUSION and FUTURE STUDIES 
5.1 SUMMARY           96 
5.2 REFERENCES           98
  9
LIST OF FIGURES 
1.1 Metabolic pathways for the conversion of linoleic acid and     3  
α-linolenic acid into LCPUFA. 
1.2 Conversion of linoleic acid to arachidonic acid.       4 
2.1 Summary of baboon neonate formula consumption and growth.   47 
2.2 Baboon neonate FA concentrations at 12 weeks of age.    49 
3.1 Regression analysis calculation for RBC, Hemoglobin,  
Hematocrit and RDW.                                65 
3.2 Regression analysis calculation for MCV, MCH and MCHC.   69 
4.1 Clinical chemistry parameters influenced by dietary LCPUFA.   88
 x 
LIST OF TABLES 
1.1 Common dietary sources of n-6 and n-3 fatty acids.         3 
1.2 Target LCPUFA concentrations in US commercial term infant formulas.             21 
2.1 Characteristics of baboon neonate groups.        34 
2.2 Nutrient content of Enfamil® LIPIL®         35 
2.3 Liver, RBC, plasma and heart FA composition.           41 
2.4 Cerebral cortex precentral gyrus and frontal lobes and retina FA 
composition.            43 
2.5 Basal ganglia (globus pallidus, putamen, caudate) and amygdala FA 
composition.            44 
2.6 Superior and inferior colliculi FA composition.        46 
3.1 Characteristics of baboon neonate groups.        63 
4.1 Characteristics of baboon neonate groups.         84 
4.2 Changes in clinical chemistry parameters for baboon neonates at 6 and     
12 weeks of age.           88 
4.3 Ontogeny of white cell parameters for baboon neonates from 2 to  
12 weeks of age.           90 
 xi 
  LIST OF ABBREVIATIONS 
 
ALA, α-linolenic acid (18:3n-3) 
ARA, arachidonic acid (20:4n-6) 
C, Control formula: DHA (0%w/w), ARA (0%w/w) 
CBC, complete blood count 
CNS, central nervous system 
DHA, docosahexaenoic acid (22:6n-3) 
DHGLA, dihomo-γ-linolenic acid (20:3n-6)  
DPA,   docosapentaenoic acid (22:5n-3, 22:5n-6) 
EDTA, ethylenediaminetetraacetic acid 
EFA, essential fatty acid 
EPA, eicosapentaenoic acid (20:5n-3) 
EPO, erythropoietin  
ERG, electroretinography  
FA, fatty acid 
FAME, fatty acid methyl ester 
GC, gas chromatography 
GI, gastrointestinal tract 
GLA γ-linolenic acid (18:3n-6) 
IUGR, intrauterine growth restriction 
L, LCPUFA intermediate formula:  DHA (0.32%), ARA (0.64%) 
L3, LCPUFA high formula:  DHA (0.96%), ARA (0.64%)  
LA, linoleic acid (18:2n-6) 
LCPUFA, (≥20 carbons) long-chain polyunsaturated fatty acids 
MCV, mean cell volume  
 xii 
MCH, mean cell hemoglobin  
MCHC, mean cell hemoglobin concentrations  
MDI, Mental Development Index 
MPV, mean platelet volumes  
MS, mass spectrometry 
MUFA, monounsaturated fatty acids 
NEC, necrotizing enterocolitis 
NHP, non-human primate 
PDI, Psychomotor Development Index 
RBC, red blood cells 
RDW, red blood cell distribution width  
SID, Bayley Scales of Infant Development 
SFA, saturated fatty acids 
VEP, visual evoked potential 
VLBW, very low-birth weight 
WBC, white blood cell   
w/w, weight ratio of FA to total FA 
